SMS Lifesciences gets zero USFDA observations for Kazipally facility
Advertisement
Telangana: SMS Lifesciences India has recently announced that the United States Food and Drug Administration (USFDA) has concluded an inspection with zero observations at its API's manufacturing facility located at Kazipally, Jinnaram MandaI, Sangareddy district, Telangana (Unit I ).
"We are glad to inform you that the Company has completed the United States Food and Drug Administration (USFDA) inspection at its API' s manufacturing facility located at Sy. NO.180/2, Kazipally, Jinnaram MandaI, Sangareddy district, Telangana (Unit I ), without any observations," the company said in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.